OVAIS KHALID: Open Payments
NPI 1033345954 · SALISBURY, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,327 in 65 payments from 13 companies in 2025. Trend: 2023 $583 · 2024 $629 · 2025 $1,327
Food & beverage: $1,300Education: $27
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 13 | $297 |
| ABBVIE INC. | 16 | $286 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $211 |
| Otsuka America Pharmaceutical, Inc. | 5 | $107 |
| Lundbeck LLC | 5 | $95 |
| Vanda Pharmaceuticals Inc. | 3 | $94 |
| Axsome Therapeutics, Inc. | 3 | $59 |
| Janssen Pharmaceuticals, Inc | 2 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Neurocrine BioSciences, Inc. | 2 | $37 |
Products named: COBENFY, VRAYLAR, CAPLYTA, REXULTI, HETLIOZ, Auvelity, ABILIFY ASIMTUFII, ABILIFY MAINTENA.
Industry payments across MD — which companies pay providers there.
